| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 55.81 | 0.33 (+0.59%) | 24.12 - 58.07 | 8.7 million (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 55.30 |
|---|---|
| Previous Close | 55.48 |
| Day's Range | 54.90 - 56.35 |
| Market Cap | 85.1B |
| Avg Volume (10 Day) | 13.0M |
| Price/Earnings (Trailing 12 Mo.) | 31.3x |
| Earnings Per Share (Trailing 12 Mo.) | 1.79 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
Business Wire - Tuesday 05/21/2013 4:30 PM ET
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
Business Wire - Friday 05/17/2013 4:05 PM ET
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
Business Wire - Wednesday 05/15/2013 6:30 PM ET
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
Business Wire - Tuesday 05/14/2013 4:05 PM ET
Gilead Sciences Announces First Quarter 2013 Financial Results
Business Wire - Thursday 05/02/2013 4:05 PM ET
Gilead Reports Interim Data From Phase 2 LONESTAR Study
Business Wire - Thursday 05/02/2013 8:30 AM ET
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Business Wire - Monday 04/29/2013 8:30 AM ET
Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013
Business Wire - Thursday 04/25/2013 4:30 PM ET
| GILD | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 13.84% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.81 | |
| LT Debt/Equity | 0.72 | |
| Earnings Yield | 3.19% | |
| Price/Sales | 8.55 |
| Company | Last | Change |
|---|---|---|
| Amgen Inc | 105.91 | +0.27% |
| Biogen Idec Inc | 235.24 | +1.13% |
| Celgene Corp | 122.58 | -0.86% |
| Regeneron Pharmaceuticals Inc | 250.31 | -1.79% |
| Alexion Pharmaceuticals Inc | 99.17 | -0.71% |
Data is delayed by at least 15 min.